RT @NEJM: This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in pa…
PETAL trial: Continuous cisatracurium infusion vs usual care with lighter sedation levels, 1006 patients with moderate-to-severe ARDS, the trial was stopped for futility. No difference in mortality at 90 days https://t.co/IfY2L3qh0s
RT @NEJM: This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in pa…
RT @ATSCritCare: Read the full trial: https://t.co/8tvh1Qngy9
RT @NEJM: This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in pa…
RT @NEJM: This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in pa…
Check out the full study in @NEJM https://t.co/Y39Bf06PPI
RT @NEJM: This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in pa…
This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in patients with acute respiratory distress syndrome (ARDS). See the results of the new trial: https://t.co/lcLOUirsOM #ATS2019
RT @ATSCritCare: Read the full trial: https://t.co/8tvh1Qngy9
Read the full trial: https://t.co/8tvh1Qngy9
RT @JBLascarrou: Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome | NEJM https://t.co/7LaTusuqsL
Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome | NEJM https://t.co/7LaTusuqsL